La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Ocular Therapeutix Résultats passés
Passé contrôle des critères 0/6
Ocular Therapeutix has been growing earnings at an average annual rate of 0.6%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 39.4% per year.
Informations clés
0.6%
Taux de croissance des bénéfices
18.5%
Taux de croissance du BPA
Pharmaceuticals Croissance de l'industrie | 6.0% |
Taux de croissance des recettes | 39.4% |
Rendement des fonds propres | -36.6% |
Marge nette | -226.5% |
Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
Earnings Update: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts
Aug 10Ocular Therapeutix: A Speculative Investment For Risk-Tolerant Investors
Jul 23Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stocks Shoot Up 41% But Its P/S Still Looks Reasonable
Jul 15Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Could Be 45% Below Their Intrinsic Value Estimate
Jun 05Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results
Jun 01Ocular Therapeutics' Impressive Surge: A Strategic Insight
Mar 19Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement
Feb 11Ocular Therapeutix Vies With Gene Therapies, Not Just Eylea, For Wet AMD
Jan 10Optimistic Investors Push Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Up 31% But Growth Is Lacking
Jan 09Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?
Oct 15Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?
Jun 30Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers
Mar 08Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?
Feb 11Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Are More Bearish Than They Used To Be
Nov 16Despite Lacking Profits Ocular Therapeutix (NASDAQ:OCUL) Seems To Be On Top Of Its Debt
Sep 09Ocular Therapeutix: Trading Ahead Of An Underappreciated Catalyst Event
Aug 15Ventilation des recettes et des dépenses
Comment Ocular Therapeutix gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
30 Jun 24 | 61 | -138 | 89 | 0 |
31 Mar 24 | 60 | -115 | 79 | 0 |
31 Dec 23 | 58 | -81 | 74 | 0 |
30 Sep 23 | 58 | -67 | 76 | 0 |
30 Jun 23 | 55 | -91 | 77 | 0 |
31 Mar 23 | 52 | -89 | 75 | 0 |
31 Dec 22 | 51 | -71 | 72 | 0 |
30 Sep 22 | 50 | -59 | 70 | 0 |
30 Jun 22 | 50 | -33 | 69 | 0 |
31 Mar 22 | 49 | -22 | 68 | 0 |
31 Dec 21 | 44 | -7 | 67 | 0 |
30 Sep 21 | 39 | -88 | 64 | 0 |
30 Jun 21 | 32 | -103 | 59 | 0 |
31 Mar 21 | 22 | -131 | 53 | 0 |
31 Dec 20 | 17 | -156 | 49 | 0 |
30 Sep 20 | 12 | -96 | 49 | 0 |
30 Jun 20 | 7 | -103 | 49 | 0 |
31 Mar 20 | 6 | -91 | 50 | 0 |
31 Dec 19 | 4 | -86 | 47 | 0 |
30 Sep 19 | 2 | -78 | 41 | 0 |
30 Jun 19 | 2 | -74 | 34 | 0 |
31 Mar 19 | 2 | -63 | 27 | 0 |
31 Dec 18 | 2 | -60 | 24 | 0 |
30 Sep 18 | 2 | -56 | 20 | 0 |
30 Jun 18 | 2 | -56 | 22 | 0 |
31 Mar 18 | 2 | -61 | 27 | 0 |
31 Dec 17 | 2 | -63 | 31 | 0 |
30 Sep 17 | 2 | -63 | 33 | 0 |
30 Jun 17 | 2 | -57 | 29 | 0 |
31 Mar 17 | 2 | -50 | 23 | 0 |
31 Dec 16 | 2 | -45 | 18 | 0 |
30 Sep 16 | 2 | -43 | 16 | 0 |
30 Jun 16 | 2 | -44 | 15 | 0 |
31 Mar 16 | 2 | -43 | 14 | 0 |
31 Dec 15 | 2 | -40 | 13 | 0 |
30 Sep 15 | 2 | -37 | 12 | 0 |
30 Jun 15 | 2 | -33 | 11 | 0 |
31 Mar 15 | 1 | -29 | 10 | 0 |
31 Dec 14 | 1 | -29 | 9 | 0 |
30 Sep 14 | 0 | -24 | 7 | -8 |
30 Jun 14 | 0 | -20 | 5 | -5 |
31 Mar 14 | 0 | -17 | 4 | -2 |
Des revenus de qualité: OCUL is currently unprofitable.
Augmentation de la marge bénéficiaire: OCUL is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: OCUL is unprofitable, but has reduced losses over the past 5 years at a rate of 0.6% per year.
Accélération de la croissance: Unable to compare OCUL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: OCUL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).
Rendement des fonds propres
ROE élevé: OCUL has a negative Return on Equity (-36.63%), as it is currently unprofitable.